TY - JOUR
T1 - Hepatic arterial infusion with floxuridine and cisplatin
T2 - Overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer
AU - Patt, Y. Z.
AU - Boddie, A. W.
AU - Charnsangavej, C.
AU - Ajani, J. A.
AU - Wallace, S.
AU - Soski, M.
AU - Claghorn, L.
AU - Mavligit, G. M.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1986
Y1 - 1986
N2 - Cisplatin (CDDP) was combined with floxuridine (FUDR) and delivered into the hepatic arteries of 29 patients as induction therapy for colorectal cancer metastatic to the liver. Mitomycin C and FUDR combination was substituted after progression or when response had peaked. Chemotherapy was delivered with an Infusaid pump (Infusaid Corp; Norwood, Mass; 14 patients), Medtronic programmable drug administration device (Medtronic, Inc, Minneapolis; two patients), or percutaneously placed catheters (13 patients). Complete disappearance of liver metastases was observed in four patients and 11 additional patients had a partial remission as determined by computed tomography (CT) scan and substantiated at times by angiography, for a total response rate of 52%. Response as determined by imaging techniques coincided with a concurrent decrease in carcinoembryonic antigen (CEA) and improvement in performance status. The severity of tumor burden was correlated with the response to therapy and survival. Among those patients who responded to arterial chemotherapy, differences in disease severity did not significantly influence survival. Median survival among responders with >25% liver replacement by tumor was 14 months (P = .28), compared with 28 months for those patients with <25% liver replacement. In contrast, differences in tumor burden significantly affected survival among patients who failed to respond to chemotherapy; median survival among nonresponding patients with >25% liver replacement was 4 months, compared with 8 months for those who had <25% liver replacement (P = .01). The presence of minimal extrahepatic disease at the time of initiation of intraarterial treatment did not seem to have a significant detrimental effect on survival. The study suggests that hepatic tumor response to arterial administration of CDDP and FUDR and mitomycin C and FUDR is clinically significant because it overrides the effect of tumor burden on survival among patients who have colorectal cancer with liver metastases and may offer effective palliation.
AB - Cisplatin (CDDP) was combined with floxuridine (FUDR) and delivered into the hepatic arteries of 29 patients as induction therapy for colorectal cancer metastatic to the liver. Mitomycin C and FUDR combination was substituted after progression or when response had peaked. Chemotherapy was delivered with an Infusaid pump (Infusaid Corp; Norwood, Mass; 14 patients), Medtronic programmable drug administration device (Medtronic, Inc, Minneapolis; two patients), or percutaneously placed catheters (13 patients). Complete disappearance of liver metastases was observed in four patients and 11 additional patients had a partial remission as determined by computed tomography (CT) scan and substantiated at times by angiography, for a total response rate of 52%. Response as determined by imaging techniques coincided with a concurrent decrease in carcinoembryonic antigen (CEA) and improvement in performance status. The severity of tumor burden was correlated with the response to therapy and survival. Among those patients who responded to arterial chemotherapy, differences in disease severity did not significantly influence survival. Median survival among responders with >25% liver replacement by tumor was 14 months (P = .28), compared with 28 months for those patients with <25% liver replacement. In contrast, differences in tumor burden significantly affected survival among patients who failed to respond to chemotherapy; median survival among nonresponding patients with >25% liver replacement was 4 months, compared with 8 months for those who had <25% liver replacement (P = .01). The presence of minimal extrahepatic disease at the time of initiation of intraarterial treatment did not seem to have a significant detrimental effect on survival. The study suggests that hepatic tumor response to arterial administration of CDDP and FUDR and mitomycin C and FUDR is clinically significant because it overrides the effect of tumor burden on survival among patients who have colorectal cancer with liver metastases and may offer effective palliation.
UR - http://www.scopus.com/inward/record.url?scp=0022922415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022922415&partnerID=8YFLogxK
U2 - 10.1200/JCO.1986.4.9.1356
DO - 10.1200/JCO.1986.4.9.1356
M3 - Article
C2 - 2943876
AN - SCOPUS:0022922415
SN - 0732-183X
VL - 4
SP - 1356
EP - 1364
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 9
ER -